Overview and Scope
Kernicterus is a rare neurological condition that can occur in newborns with severe jaundice, a condition characterized by high levels of bilirubin in the blood. Kernicterus treatment refers to the medical interventions, therapies, and supportive care provided to individuals, typically infants and children. This treatment aims to address kernicterus’s symptoms, complications, and long-term effects and improve the quality of life for affected individuals.
Sizing and Forecast
The kernicterus treatment market size has grown steadily in recent years. It will grow from $2.88 billion in 2023 to $2.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to improvements in neonatal care practices, increased awareness among healthcare professionals, government initiatives for maternal and child health, research funding and clinical trials, collaborations in medical research..
The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%. The growth in the forecast period can be attributed to continuous medical education programs, global health policies and initiatives, patient advocacy and support groups, international collaboration in pediatric research, government funding for neonatal health.. Major trends in the forecast period include advancements in neonatal jaundice monitoring technologies, introduction of phototherapy devices with enhanced features, development of bilirubin-reducing medications, focus on home-based phototherapy solutions, implementation of bilirubin nomograms and guidelines, integration of telehealth for remote monitoring..
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/kernicterus-treatment-global-market-report
Segmentation & Regional Insights
The kernicterus treatment market covered in this report is segmented –
1) By Treatment: Phototherapy, Intravenous Immunoglobulins (IVIG), Blood Transfusion, Medication, Other Treatments
2) By Symptoms: Jaundice, Unusual Eye Movements, Vomiting, Fever, Poor Feeding, Apnoea, Irritability, Seizures, Sleepiness, Other Symptoms
3) By Dosage: Injection, Solution, Other Dosages
4) By End-Users: Clinic, Hospital, Other End-Users
North America was the largest region in the kernicterus treatment market in 2023. The regions covered in the kernicterus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13470&type=smp
Major Driver Impacting Market Growth
The prevalence of neonatal jaundice is driving the growth of the kernicterus treatment market going forward. Neonatal jaundice, also known simply as jaundice in newborns, is a common and typically harmless condition characterized by the yellowing of a baby’s skin and the whites of their eyes. Kernicterus treatment is commonly used for neonatal jaundice; it manages the symptoms and provides supportive care. This procedure removes blood from the baby and replaces it with blood with a lower bilirubin level, improving the affected child’s quality of life. For instance, in August 2023, according to reports published by the National Library of Medicine, a US-based biomedical library, globally, about 1.1 million babies each year develop severe neonatal hyperbilirubinemia (neonatal jaundice). Furthermore, in February 2021, according to ClinMed International Library, a US-based publishing company, it was estimated that at least 114,000 infants die yearly from neonatal hyperbilirubinemia (neonatal jaundice). Therefore, the prevalence of neonatal jaundice is expected to propel the growth of the kernicterus treatment market.
Key Industry Players
Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd , Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc.</b
The kernicterus treatment market report table of contents includes:
1. Executive Summary
2. Kernicterus Treatment Market Characteristics
3. Kernicterus Treatment Market Trends And Strategies
4. Kernicterus Treatment Market – Macro Economic Scenario
5. Global Kernicterus Treatment Market Size and Growth
.
.
.
32. Global Kernicterus Treatment Market Competitive Benchmarking
33. Global Kernicterus Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Kernicterus Treatment Market
35. Kernicterus Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
